Depression, Drug Addiction, Dual Diagnosis
Conditions
Brief summary
Methamphetamine (MA) addiction is a public health concern that causes substantial harm to individual users, and imposes an economic burden in the U.S. totaling up to $48.3 billion annually. This study proposes to address a critical aspect of this problem: the lack of any proven, FDA-approved pharmacological treatments for MA users. The proposal combines an intervention designed to improve energy metabolism in the brain, and a neuroimaging technique capable of measuring the neurochemicals that represent cerebral bioenergetic function. The study will replicate and extend a key neuroimaging finding from the investigators recent MA studies: that MA users have decreased phosphocreatine (PCr) levels in the brain, compared to healthy volunteers. Phosphocreatine is the substrate reservoir for the creatine kinase reaction, which reversibly converts PCr into adenosine triphosphate (ATP), the brain's major energy supply, and creatine. Neuronal energy demands are met through a shift in reaction equilibrium, which is designed to maintain the concentration of ATP constant. Research results from the investigators recent study also showed that female MA users have lower brain PCr levels compared to male users. These findings join the converging lines of evidence that MA use is associated with mitochondrial dysfunction, i.e. deficient energy metabolism, in the brain. Frequently, MA users also experience depression, as well as cognitive deficits. Interestingly, both of these entities are also linked to mitochondrial dysfunction in the brain. The long-term goal of this research program is to define the alterations in brain chemistry that underlie MA use disorders, and to utilize translational magnetic resonance spectroscopy (MRS) neuroimaging to identify rational brain-based treatment targets. Once a hypothesis-driven intervention is identified, MRS can then be further employed in treatment studies, to verify that target engagement is achieved. The specific aims of this proposal are an example of this stepwise scientific process: the nutritional supplement creatine will be tested in a randomized, placebo-controlled study of women with MA use disorders, to investigate creatine's effect on cerebral PCr levels, depressive symptoms, and MA usage.
Interventions
Sponsors
Study design
Eligibility
Inclusion criteria
* Female gender, ages 18-55 inclusive * Current primary diagnosis of MA dependence or abuse, with MA preferred drug of abuse * Current diagnosis of Major Depressive Disorder * Current HAMD score \> 15 * Clinical Global Impressions Severity depression score \> 4 * If currently taking a psychotropic medication for depressed mood, regimen must be stable for \> 4 weeks before randomization
Exclusion criteria
* Persons unable to provide adequate consent * Persons who are at clinically significant suicidal or homicidal risk * Primary substance-related diagnosis other than MA dependence or abuse * Comorbid substance dependence diagnosis, other than nicotine (substance abuse diagnoses are not excluded) * Positive pregnancy test * Positive test for the antibody to the Human Immunodeficiency Virus (HIV) * History of renal disease
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Hamilton Depression Rating Scale (HAMD) Scores | 8-weeks | Change in Hamilton Depression Rating Scale (HAMD) scores will be evaluated over the course of the 8-week treatment period. The HAMD provides an indication of depression and over time provides a valuable guide to progress. Total score ranges from 0 to 54. 0 means no depression and 24 and above means severe depression. |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| Beck Anxiety Inventory (BAI) Scores | 8-weeks | Change in Beck Anxiety Inventory (BAI) scores will be evaluated over the course of the 8-week treatment period. The BAI aims to assess the severity of anxiety symptoms, helping clinicians and researchers understand the level of anxiety an individual is experiencing. 0 means minimal anxiety and 30-63 means severe anxiety. The scale ranges from 0 to 63. Total score is reported. |
Other
| Measure | Time frame | Description |
|---|---|---|
| BL Neurochemistry Measured by Magnetic Resonance Spectroscopy | Baseline | Neurochemistry, such as phosphocreatine (PCr), will be measured pre- and post-creatine/placebo treatment. |
| Neurochemistry Measured by Magnetic Resonance Spectroscopy TX | 8-weeks | Neurochemistry, such as phosphocreatine (PCr), will be measured pre- and post-creatine/placebo treatment. |
Countries
United States
Participant flow
Recruitment details
We complied with safety measures meant to minimize the risk of exposure to COVID-19. Participant recruitment were facilitated by advertisements in newspapers, on the radio, by hanging recruitment materials, on the Internet, and by sending letters to social workers and staff at treatment centers. To increase the study's enrollment of healthy controls, we distributed materials specifically aimed at healthy controls.
Participants by arm
| Arm | Count |
|---|---|
| Creatine Monohydrate 5 grams of daily creatine monohydrate for 8 weeks
Creatine monohydrate | 21 |
| Placebo 5 g of placebo for 8 weeks
Creatine monohydrate | 20 |
| Healthy Control Measured at baseline. | 24 |
| Total | 65 |
Baseline characteristics
| Characteristic | Creatine Monohydrate | Placebo | Healthy Control | Total |
|---|---|---|---|---|
| Age, Categorical <=18 years | 0 Participants | 0 Participants | 0 Participants | 0 Participants |
| Age, Categorical >=65 years | 0 Participants | 0 Participants | 0 Participants | 0 Participants |
| Age, Categorical Between 18 and 65 years | 21 Participants | 20 Participants | 24 Participants | 65 Participants |
| Age, Continuous | 37.4 years STANDARD_DEVIATION 7.1 | 34.2 years STANDARD_DEVIATION 10 | 30.8 years STANDARD_DEVIATION 10.5 | 33.8 years STANDARD_DEVIATION 9.6 |
| Race/Ethnicity, Customized Race Asian | 0 Participants | 0 Participants | 2 Participants | 2 Participants |
| Race/Ethnicity, Customized Race Caucasian | 18 Participants | 17 Participants | 18 Participants | 53 Participants |
| Race/Ethnicity, Customized Race Hispanic/Latino | 3 Participants | 2 Participants | 4 Participants | 9 Participants |
| Race/Ethnicity, Customized Race More than one race | 0 Participants | 0 Participants | 0 Participants | 0 Participants |
| Race/Ethnicity, Customized Race Native American | 0 Participants | 1 Participants | 0 Participants | 1 Participants |
| Region of Enrollment United States | 21 participants | 20 participants | 24 participants | 65 participants |
| Sex: Female, Male Female | 21 Participants | 20 Participants | 24 Participants | 65 Participants |
| Sex: Female, Male Male | 0 Participants | 0 Participants | 0 Participants | 0 Participants |
Adverse events
| Event type | EG000 affected / at risk | EG001 affected / at risk | EG002 affected / at risk |
|---|---|---|---|
| deaths Total, all-cause mortality | 0 / 21 | 0 / 20 | 0 / 24 |
| other Total, other adverse events | 3 / 21 | 7 / 20 | 0 / 24 |
| serious Total, serious adverse events | 0 / 21 | 0 / 20 | 0 / 24 |
Outcome results
Hamilton Depression Rating Scale (HAMD) Scores
Change in Hamilton Depression Rating Scale (HAMD) scores will be evaluated over the course of the 8-week treatment period. The HAMD provides an indication of depression and over time provides a valuable guide to progress. Total score ranges from 0 to 54. 0 means no depression and 24 and above means severe depression.
Time frame: 8-weeks
Population: Due to participant attrition, data analyzed in one or more rows differed from the overall number analyzed.
| Arm | Measure | Group | Value (MEAN) | Dispersion |
|---|---|---|---|---|
| Creatine Monohydrate | Hamilton Depression Rating Scale (HAMD) Scores | Baseline Scan | 16.24 score on a scale | Standard Deviation 3.91 |
| Creatine Monohydrate | Hamilton Depression Rating Scale (HAMD) Scores | Screening | 16.76 score on a scale | Standard Deviation 3.33 |
| Creatine Monohydrate | Hamilton Depression Rating Scale (HAMD) Scores | Week 8 Final Scan | 9.33 score on a scale | Standard Deviation 3.58 |
| Placebo | Hamilton Depression Rating Scale (HAMD) Scores | Baseline Scan | 14.90 score on a scale | Standard Deviation 4.1 |
| Placebo | Hamilton Depression Rating Scale (HAMD) Scores | Screening | 17.65 score on a scale | Standard Deviation 4.66 |
| Placebo | Hamilton Depression Rating Scale (HAMD) Scores | Week 8 Final Scan | 8.18 score on a scale | Standard Deviation 7.26 |
| Healthy Control | Hamilton Depression Rating Scale (HAMD) Scores | Screening | 1.67 score on a scale | Standard Deviation 1.9 |
| Healthy Control | Hamilton Depression Rating Scale (HAMD) Scores | Week 8 Final Scan | 1.88 score on a scale | Standard Deviation 2.58 |
| Healthy Control | Hamilton Depression Rating Scale (HAMD) Scores | Baseline Scan | 1.58 score on a scale | Standard Deviation 2.21 |
Beck Anxiety Inventory (BAI) Scores
Change in Beck Anxiety Inventory (BAI) scores will be evaluated over the course of the 8-week treatment period. The BAI aims to assess the severity of anxiety symptoms, helping clinicians and researchers understand the level of anxiety an individual is experiencing. 0 means minimal anxiety and 30-63 means severe anxiety. The scale ranges from 0 to 63. Total score is reported.
Time frame: 8-weeks
Population: Due to participant attrition, data analyzed on one or more rows differ from the overall number analyzed.
| Arm | Measure | Group | Value (MEAN) | Dispersion |
|---|---|---|---|---|
| Creatine Monohydrate | Beck Anxiety Inventory (BAI) Scores | Week 8 Final Scan | 6.00 score on a scale | Standard Deviation 5.2 |
| Creatine Monohydrate | Beck Anxiety Inventory (BAI) Scores | Screening | 22.76 score on a scale | Standard Deviation 12.7 |
| Creatine Monohydrate | Beck Anxiety Inventory (BAI) Scores | Baseline | 20.81 score on a scale | Standard Deviation 12 |
| Placebo | Beck Anxiety Inventory (BAI) Scores | Baseline | 24.60 score on a scale | Standard Deviation 13.56 |
| Placebo | Beck Anxiety Inventory (BAI) Scores | Week 8 Final Scan | 12.82 score on a scale | Standard Deviation 18 |
| Placebo | Beck Anxiety Inventory (BAI) Scores | Screening | 29.25 score on a scale | Standard Deviation 12.08 |
| Healthy Control | Beck Anxiety Inventory (BAI) Scores | Screening | 3.63 score on a scale | Standard Deviation 4.67 |
| Healthy Control | Beck Anxiety Inventory (BAI) Scores | Week 8 Final Scan | 3.64 score on a scale | Standard Deviation 4.23 |
| Healthy Control | Beck Anxiety Inventory (BAI) Scores | Baseline | 4.13 score on a scale | Standard Deviation 4.67 |
BL Neurochemistry Measured by Magnetic Resonance Spectroscopy
Neurochemistry, such as phosphocreatine (PCr), will be measured pre- and post-creatine/placebo treatment.
Time frame: Baseline
Population: Phosphocreatine (Baseline comparison between creatine and placebo)
| Arm | Measure | Value (MEAN) |
|---|---|---|
| Creatine Monohydrate | BL Neurochemistry Measured by Magnetic Resonance Spectroscopy | 0.268 ratio |
| Placebo | BL Neurochemistry Measured by Magnetic Resonance Spectroscopy | 0.268 ratio |
Neurochemistry Measured by Magnetic Resonance Spectroscopy TX
Neurochemistry, such as phosphocreatine (PCr), will be measured pre- and post-creatine/placebo treatment.
Time frame: 8-weeks
Population: Phosphocreatine (Treatment comparison between creatine and placebo)
| Arm | Measure | Value (MEAN) |
|---|---|---|
| Creatine Monohydrate | Neurochemistry Measured by Magnetic Resonance Spectroscopy TX | 0.291 ratio |
| Placebo | Neurochemistry Measured by Magnetic Resonance Spectroscopy TX | 0.269 ratio |